COMMUNIQUÉS West-GlobeNewswire

LIDDS: LIDDS and Recipharm establish industrial manufacturing capabilities for a novel prostate cancer product
20/07/2017
LIDDS and Recipharm, the contract development and manufacturing organisation (CDMO), have together set up a manufacturing line for LIDDS' novel prostate cancer drug, Liproca® Depot, at Recipharm in Solna, Sweden. The [...]
Enzymatica AB: Continued sales growth and breakthrough order from STADA
20/07/2017
Enzymatica Interim report Jan-june2017 This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients. The issuer of this announcement warrants that they are [...]
Basilea announces completion of the license agreement with Pfizer for antifungal Cresemba® for Europe, Russia, Turkey and Israel
20/07/2017
Basel, Switzerland, July 20, 2017 - Basilea Pharmaceutica Ltd. (SIX: BSLN) reported today that its license agreement with Pfizer Inc. (NYSE: PFE) for Basilea's antifungal Cresemba (isavuconazole), which was announced on [...]
ABLYNX AND SANOFI ENTER INTO A STRATEGIC COLLABORATION TO DEVELOP NANOBODY PRODUCT CANDIDATES FOCUSED ON IMMUNE-MEDIATED INFLAMMATORY DISEASES
20/07/2017
REGULATED INFORMATION GHENT, Belgium, 20 July 2017 - Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced that it has entered into a research collaboration and global exclusive licensing agreement with Sanofi [...]
EDAP to Host Webcast Discussing HIFU Devices with an American Key Opinion Leader
19/07/2017
Webcast to be held Thursday, July 27 th , 2017 LYON, France, July 18, 2017 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, today announced that the Company plans to host an [...]
Diaxonhit : Acquisition de la société de diagnostic médical GENBIO aux Etats-Unis
19/07/2017
DIAXONHIT annonce l'acquisition de la société GENBIO aux Etats-Unis Acquisition stratégique d'une entreprise commerciale pour accélérer le développement du groupe aux Etats-Unis, tout en renforçant son catalogue de [...]
Summit Therapeutics plc : Grant of Share Options and Restricted Stock Units
19/07/2017
Summit Therapeutics plc ('Summit' or the 'Company') GRANT OF SHARE OPTIONS TO DIRECTORS, PDMRS AND EMPLOYEES AND GRANT OF RESTRICTED STOCK UNITS TO NON-EXECUTIVE DIRECTORS Oxford, UK, 19 July 2017 - Summit Therapeutics [...]
Medibio building credentials to "scale" via appointment of healthcare & telehealth icon to Board of Directors
19/07/2017
SYDNEY, Australia and MINNEAPOLIS, July 19, 2017 (GLOBE NEWSWIRE) -- Medibio Limited ( MEB or the Company ) (ASX:MEB) (OTCQB:MDBIF), a digital health company that has developed an objective testing system to assist in [...]
ProMIS Neurosciences Presents at AAIC 2017 Data from Alzheimer's Disease Program
19/07/2017
Company Focused on Development of Antibodies that Selectively Target Toxic, Prion-Like Forms of Amyloid beta ProMIS Issues White Paper from AAIC Presentations Outlining Role of Toxic Misfolded Forms of Amyloid beta and [...]
Orion Group Half-Year Financial Report January-June 2017
19/07/2017
ORION CORPORATION HALF-YEAR FINANCIAL REPORT JANUARY-JUNE 2017 19 JULY 2017 AT 13.15 EEST Orion Group Half-Year Financial Report January-June 2017 Orion's net sales in January-June 2017 totalled EUR 552 million (EUR 535 [...]
Orion Corporation's financial reporting and Annual General Meeting in 2018
19/07/2017
ORION CORPORATION STOCK EXCHANGE RELEASE 19 JULY 2017 at 11.00 A.M. EEST Orion Corporation's financial reporting and Annual General Meeting in 2018 Orion Corporation will publish its Financial Statement Release 2017 on [...]
RECORDATI: THE EUROPEAN COMMISSION APPROVES REAGILA® (CARIPRAZINE) FOR THE TREATMENT OF SCHIZOPHRENIA
19/07/2017
Milan, 19 July 2017 - Recordati announces that Gedeon Richter Plc. was granted marketing authorization from the European Commission for Reagila® (cariprazine), a novel antipsychotic for the treatment of schizophrenia in [...]
MPI: OV to evaluate the potential of in-licensing a small molecule compound for development in cancer from a major Pharmaceutical company
19/07/2017
Hoersholm, Denmark, July 19, 2017 - Oncology Venture AB (OV:ST) and Novartis Pharma AG (Basel, Switzerland) have entered into an agreement providing Oncology Venture with an option right to execute an exclusive license [...]
NEOVACS obtient une nouvelle « Investigational New Drug (IND) » de la FDA dans la dermatomyosite aux Etats-Unis
19/07/2017
COMMUNIQUE DE PRESSE · COMMUNIQUE DE PRESSE · COMMUNIQUE DE PRESSE Néovacs annonce avoir obtenu une nouvelle « Investigational New Drug ( IND ) » de la FDA pour élargir son programme de développement clinique avec l' [...]
Neovacs Announces FDA Acceptance of a New IND to Expand in U.S. IFNalpha Kinoid Clinical Development Program in Dermatomyositis
19/07/2017
PRESS RELEASE · PRESS RELEASE · PRESS RELEASE Neovacs Announces FDA Acceptance of a New IND to Expand in U.S. IFNalpha Kinoid Clinical Development Program in Dermatomyositis This is the second clinical trial approved by [...]
ELSALYS BIOTECH et le prestigieux institut allemand de recherche sur le cancer DKFZ initient le développement d'ELB021 dans la leucémie à cellules B avec le soutien de l'Union Européenne
18/07/2017
ELSALYS BIOTECH et le prestigieux institut allemand de recherche sur le cancer DKFZ initient le développement d'ELB021 dans la leucémie à cellules B avec le soutien de l'Union Européenne ELB021 est un anticorps [...]
ELSALYS BIOTECH and the prestigious German cancer research institute DKFZ initiate the development of ELB021 in B-Cell leukemia with the support of EU
18/07/2017
ELSALYS BIOTECH and the prestigious German cancer research institute DKFZ initiate the development of ELB021 in B-Cell leukemia with the support of EU ELB021 is a proprietary first-in-class monoclonal antibody targeting [...]
PHARMAGEST INTERACTIVE : acquisition majeure sur le marché de l'informatique hospitalière
18/07/2017
Villers-lès-Nancy, le 18 Juillet 2017 - 19h00 (CET) COMMUNIQUE DE PRESSE SYSTEME D'INFORMATION DE SANTE A L'HOPITAL ACQUISITION MAJEURE MALTA INFORMATIQUE, filiale du Groupe PHARMAGEST ( Euronext Paris #FR 0012882389 - [...]
SPINEWAY : Croissance confirmée sur le 1er semestre 2017 Chiffre d'affaires de 6M€ (+ 146%)
18/07/2017
Communiqué de presse Ecully, le 18 juillet 2017 Croissance confirmée sur le 1 er semestre 2017 Chiffre d'affaires de 6M€ (+ 146%) En Milliers d'euros 2016 2017* 1 er trimestre 1 109 3 110 2 ème trimestre 1 330 2 901 CA [...]

Pages